T-cell-targeted biologicals for psoriasis

Curr Drug Targets Inflamm Allergy. 2004 Jun;3(2):157-61. doi: 10.2174/1568010043343912.


Psoriasis is now accepted as a T-cell-mediated disease and that targeting of T cell function and/or trafficking is a logical approach to therapy. As a consequence of recombinant DNA technologies biologic therapies are synthesisable in sufficient quantities for clinical use. The original proof of concept for T-cell-targeted therapies in psoriasis came with the demonstration that anti-CD4 monoclonal antibodies were effective. Progress is such that two T-cell-directed biologicals - alefacept and efalizumab - have recently been approved in the U.S.A. for the treatment of psoriasis. In addition to providing new therapies the T-cell-targeted biologicals with their selective approach can be used as sophisticated tools to dissect out and help our understanding of key pathomechanisms in psoriasis; the non - efficacy of anti - E-selectin is a case in point. It is likely that the most appropriate place for T-cell-directed biologicals in the management of chronic plaque psoriasis will be for maintenance, rather than induction, of remission. This is a reflection of mode of action and relative safety for long-term administration.

Publication types

  • Review

MeSH terms

  • Alefacept
  • Antibodies, Monoclonal / genetics
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Biological Factors / genetics
  • Biological Factors / pharmacology
  • Biological Factors / therapeutic use*
  • DNA, Recombinant / pharmacology
  • DNA, Recombinant / therapeutic use
  • Drug Delivery Systems / methods*
  • Humans
  • Psoriasis / drug therapy*
  • Psoriasis / metabolism
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / pharmacology
  • Recombinant Fusion Proteins / therapeutic use
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / metabolism


  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Biological Factors
  • DNA, Recombinant
  • Recombinant Fusion Proteins
  • Alefacept
  • efalizumab